EMMA ELLMAN-GROVES: Open Payments
NPI 1457815771 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,124 in 57 payments from 12 companies in 2025. Trend: 2023 $849 · 2024 $1,589 · 2025 $1,124
Food & beverage: $1,124
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $221 |
| Janssen Biotech, Inc. | 9 | $182 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $161 |
| Ardelyx, Inc. | 8 | $145 |
| GENZYME CORPORATION | 5 | $117 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| PFIZER INC. | 3 | $46 |
| Exact Sciences Corporation | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
Products named: DUPIXENT, TREMFYA, IBSRELA, RINVOQ, XIFAXAN, RELISTOR, LINZESS, SKYRIZI.
Industry payments across DE — which companies pay providers there.
